An industry-run program designed to monitor use of the popular acne drug Accutane has failed to lower rates of unplanned pregnancies and reduce the risk of birth defects in women taking the drug, a federal advisory panel was told Thursday.
An industry-run program designed to monitor use of the popular acne drug Accutane has failed to lower rates of unplanned pregnancies and reduce the risk of birth defects in women taking the drug, a federal advisory panel was told Thursday.